Aktuellt
SENASTE
Redeye is positively surprised by the favorable opinion for Tesofensine as an obesity treatment in Mexico by the technical committee of its regulatory agency. The opinion is non-binding and part of the regulatory process. We have lately seen this asset as a bonus only considering the lengthy decision-making process and lack of transparency. Saniona has the right to royalties of the sales from its partner Medix. We expect a positive reaction in the share price and will review our take on the asset following this breakthrough.
LÄS MER
